TICKERNERD
Menu
AGIOAGIOHealthcare · Biotechnology

AGIO Stock Forecast: Agios Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$34
−0.18% on the day

The 10 Wall Street analysts covering Agios Pharmaceuticals, Inc. hold a median 12-month price target of $43 — +26.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 82 of 100 as at 12 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$2.0B
Ticker Nerd rank
82 / 100
Median analyst target
$43
Analysts covering
10
Revenue$44.7M+259.3% y/y
Operating income−$110.6M
Net income−$100.7M
Free cash flow−$83.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.4%
1M
+2.7%
YTD
+23.4%
1Y
−8.0%
From 52W high
−26.2%
From 52W low
+50.3%
$22
$45
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AGIO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Agios Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
82 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
89
Quality
78
Accruals
71
Issuance
71
Growth
62
Value
60
Momentum
46
Volatility
43
Size
36

Revisions (89): Analysts have, on balance, been raising their forecasts.

Volatility (43): The share price moves around a lot.

Size (36): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AGIO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AGIO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60$70$80Oct 25Jan 26Apr 26Jul 26AGIOHigh $73Median $43Low $32

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
7 Buy3 Hold0 Sell
Low $32Median $43High $73

The green dot is the last close — the median target sits +26.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
7 Aug 2026JP MorganMaintainsNeutral$31 → $34
31 July 2026CitigroupMaintainsBuy$46 → $52
31 July 2026Truist SecuritiesMaintainsBuy$41 → $39
30 July 2026HC Wainwright & Co.MaintainsBuy$52 → $55
30 July 2026HC Wainwright & Co.MaintainsBuy—
21 July 2026HC Wainwright & Co.MaintainsBuy—
21 July 2026HC Wainwright & Co.MaintainsBuy$54 → $52
7 July 2026B of A SecuritiesMaintainsBuy—
7 July 2026B of A SecuritiesMaintainsBuy$40 → $46
7 July 2026RBC CapitalMaintainsSector Perform$28 → $32
7 July 2026RBC CapitalMaintainsSector Perform—
7 July 2026Truist SecuritiesMaintainsBuy$36 → $41
7 July 2026Truist SecuritiesMaintainsBuy—
15 June 2026HC Wainwright & Co.ReiteratesBuy—
11 June 2026JP MorganMaintainsNeutral—
29 May 2026B of A SecuritiesMaintainsBuy—
30 Apr 2026Truist SecuritiesMaintainsBuy—
21 Apr 2026B of A SecuritiesMaintainsBuy—
20 Apr 2026HC Wainwright & Co.MaintainsBuy—
6 Apr 2026JP MorganMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AGIO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

AGIO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Agios Pharmaceuticals, Inc. returned −8.0% against +17.5% for the S&P 500, dividends included.

AGIO vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Oct 25Jan 26Apr 26Jul 26AGIOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AGIO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Agios Pharmaceuticals, Inc. (AGIO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
3.8×

Cheaper than 67% of US stocks

Price / sales
20.4×

Cheaper than 9% of US stocks

Price / book
2.0×

Cheaper than 46% of US stocks

EV / EBITDA
−3.1×

Cheaper than 75% of US stocks

Growth & margins
Revenue growth (YoY)
259.3%

Higher than 96% of US stocks

Earnings growth (YoY)
259.3%

Higher than 92% of US stocks

Gross margin
93.3%

Higher than 97% of US stocks

Operating margin
−247.1%

Higher than 10% of US stocks

Net margin
88.3%

Higher than 99% of US stocks

Returns & dividend
Return on equity
−34.3%

Higher than 26% of US stocks

Return on assets
−22.2%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Agios Pharmaceuticals, Inc. (AGIO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Agios Pharmaceuticals, Inc. has a market value of $2.0B and an enterprise value of $1.4B.

  • Revenue in the twelve months to 30 June 2026: $98.3M. The latest quarter grew 259.3% year on year.

  • Net income over the same four quarters: −$411.3M, a −418.2% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$390.3M.

  • Shares outstanding: 59.6M.

  • Trailing P/E: 3.8×; forward P/E: −8.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Agios Pharmaceuticals, Inc. employs 539 people — $182K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

AGIO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AGIOAgios Pharmaceuticals, Inc.$2.0B
82
ZBIOZenas BioPharma, Inc.$2.0B
26
VCELVericel Corp.$1.9B
94
KODKodiak Sciences, Inc.$2.0B
43
GENBGenerate Biomedicines, Inc.$2.0B
1
RAPPRapport Therapeutics, Inc.$2.0B
46
ZYMEZymeworks, Inc.$1.9B
77

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Agios Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AGIO news & analysis

Agios Pharmaceuticals: Indication Stacking Is Creating A Commercial Flywheel

Seeking Alpha · 20 Aug 2026positive

Agios Pharmaceuticals is expanding mitapivat's commercial platform across PK deficiency, thalassemia, and potentially sickle cell disease. The thalassemia launch drove Q2 2026 mitapivat revenue to $44.7M, up 259% year-over-year, with strong payer coverage and operational leverage emerging. The company's $965M cash position supports pipeline expansion ahead of the November 1, 2026, PDUFA for mitapivat in sickle cell.

Why it matters — AGIO watchers would care because mitapivat's revenue growth, expanding indications, and cash position point to a strengthening rare-disease franchise ahead of a key sickle cell PDUFA decision.

AGIO Q2 Earnings Beat Estimates, Revenues Increase Year Over Year

Zacks Investment Research · 31 July 2026positive

Agios Pharmaceuticals reported second-quarter revenue and earnings that surpassed analyst estimates, driven by sales of Pyrukynd and the launch of Aqvesme, while continuing to advance its hematology pipeline.

Why it matters — An AGIO watcher would care because the company demonstrated financial momentum with its newer product launches and pipeline development, reinforcing its commercial execution in the hematology space.

Agios Pharmaceuticals, Inc. (AGIO) Q2 2026 Earnings Call Transcript

Seeking Alpha · 30 July 2026neutral

Agios Pharmaceuticals held its Q2 2026 earnings call, with the transcript of management's discussion and analyst Q&A published on Seeking Alpha.

Why it matters — The earnings call provides AGIO investors with management's commentary on financial results and business developments for the quarter.

Agios Pharmaceuticals Q2 Earnings Call Highlights

MarketBeat · 30 July 2026positive

Agios Pharmaceuticals reported second-quarter 2026 mitapivat net revenue of $44.7 million, with $40.9 million from the U.S. and $3.8 million from outside the U.S., as the company continues the U.S. thalassemia launch of AQVESME and prepares for a potential sickle cell disease approval later this year.

Why it matters — The update provides a snapshot of early commercial performance for AQVESME in thalassemia and signals an upcoming regulatory decision for sickle cell disease, both key catalysts for the company.

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research · 30 July 2026positive

Agios Pharmaceuticals reported a Q2 loss of $1.69 per share, beating the Zacks Consensus Estimate of a $1.86 loss, and improving from the $1.93 per share loss reported a year ago.

Why it matters — AGIO watchers would note that the company's quarterly result exceeded analyst expectations and showed improvement over the prior-year period.

FAQ

Frequently asked questions about AGIO stock

What is the AGIO stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Agios Pharmaceuticals, Inc. have a median 12-month price target of $43, with estimates ranging from $32 to $73. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AGIO stock a buy right now?

Of the 10 analysts covering Agios Pharmaceuticals, Inc., 7 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Agios Pharmaceuticals, Inc. 82 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AGIO?

As at 12 Sept 2026, Agios Pharmaceuticals, Inc. ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (89 of 100).

Will AGIO stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +26.6% from the last close, and Ticker Nerd's factor model ranks Agios Pharmaceuticals, Inc. 82 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AGIO stock forecast for 2030?

No analyst covering Agios Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AGIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $32 to $73 over the next 12 months.

How has AGIO stock performed over the past year?

Agios Pharmaceuticals, Inc. returned -8.0% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Agios Pharmaceuticals, Inc. do?

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing medicines for rare diseases through its expertise in cellular metabolism.

What is the latest news on AGIO?

The most recent item we track (Seeking Alpha, 20 Aug 2026): "Agios Pharmaceuticals: Indication Stacking Is Creating A Commercial Flywheel". Agios Pharmaceuticals is expanding mitapivat's commercial platform across PK deficiency, thalassemia, and potentially sickle cell disease. The thalassemia launch drove Q2 2026 mitapivat revenue to $44.7M, up 259% year-over-year, with strong payer coverage and operational leverage emerging. The company's $965M cash position supports pipeline expansion ahead of the November 1, 2026, PDUFA for mitapivat in sickle cell.

Company

About Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing medicines for rare diseases through its expertise in cellular metabolism. The company’s core commercial product is PYRUKYND (mitapivat), an oral pyruvate kinase activator used in hemolytic anemia associated with pyruvate kinase deficiency, with additional development in other hematologic and genetically defined disorders. Agios is also advancing investigational therapies for conditions such as thalassemia, sickle cell disease, and phenylketonuria, reflecting its emphasis on rare disease biology and precision medicine. The company operates as a specialized hematology and rare disease developer, combining drug discovery, clinical development, and commercialization capabilities to address unmet medical needs. Agios Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

CEO Mr. Brian M. Goff M.B.A. · 539 employees · United States · https://www.agios.com